Mechanism of action (Pharmacodynamics)
The drug's site of action is the early stage of viral replication within the host cell. Under natural conditions, viral entry involves a stage of acidification (lowering the pH within the endosome). Hydrogen ions enter the viral particle through specific ion channels formed by the M2 viral protein.
The drop in pH triggers deproteinization—the dissociation of ribonucleoproteins from the matrix protein. As a result, the viral RNA is released from the capsid into the cytoplasm for subsequent transport into the nucleus (the viral "uncoating" process).
Remantadin acts as an M2 ion channel blocker. It impedes proton transport into the virion, preventing the acidification of its internal environment. Consequently, ribonucleoprotein dissociation is disrupted, making the release of the viral genome into the cytoplasm impossible.
Additional mechanism: there is evidence of the drug affecting late stages of replication, which is associated with conformational changes in the viral hemagglutinin.
Spectrum of activity and indications
The drug has a narrow spectrum of activity: it is active exclusively against the influenza A virus. It is ineffective against the influenza B virus because the latter genetically lacks the M2 protein.
Indications for prescription:
- Prevention: during influenza epidemics (proven efficacy is 70–90%).
- Treatment: strictly at the initial stage of the disease. Early administration alleviates clinical symptoms and accelerates recovery.
Pharmacokinetics
The drug is administered orally, after meals. It exhibits high bioavailability (over 90%). An important clinical feature is its ability to cross the blood-brain barrier (BBB) and the placenta.
Unlike its predecessor (amantadine), Remantadin undergoes intensive hepatic metabolism (about 75%) and has a significantly longer half-life ($T_{1/2}$ is 24–36 hours).
Side effects and safety profile
Because the drug is lipophilic and readily crosses the BBB, major adverse reactions are associated with the Central Nervous System (CNS). Patients may experience:
- Insomnia;
- Ataxia (impaired coordination of movements);
- Impaired concentration.
Comparatively, adverse effects from remantadine occur less frequently and are less pronounced than those from amantadine.
Place in therapy and prescription rules
When choosing influenza therapy, it is important to distinguish M2 channel blockers from other groups. For example, oseltamivir (a neuraminidase inhibitor) disrupts the release of new virions from the cell, while kagocel stimulates endogenous interferon production. Drugs like enfuvirtide (a fusion inhibitor) are specific to HIV and ineffective against influenza.
Dosage form: tablets (including coated ones) of 0.05 g. The therapeutic oral dose range is 0.05–0.1 g.
Prescription example: `Rp.: Tab. Remantadini 0.05` `D.t.d. N. 20` `S. Orally, 1-2 tablets according to the schedule.`
Briefly: answers to topical questions
How does the mechanism of action of oseltamivir differ from that of remantadine?
The mechanisms of action of these drugs differ in their sites of action within the viral life cycle.
| Characteristic | Oseltamivir (Oseltamivir) | Rimantadine |
|---|---|---|
| Target | Neuraminidase enzyme | M2 protein ion channels |
| Effect | Disrupts viral release from the cell | Disrupts viral uncoating (deproteinization) |
| Spectrum | Influenza A and B viruses | Influenza A virus only |
Which drugs belong to the adamantane group and what is their common mechanism of action?
The source classifies amantadine, rimantadine, adapromine, deitiforin, and tromantadine as adamantane derivatives.
Adamantane derivatives are noted for acting on the viral deproteinization ("uncoating") stage. For amantadine and rimantadine, the specific blockade of M2 proton channels is described: it disrupts the separation of ribonucleoproteins from the matrix and the release of the viral genome into the cytoplasm.
- Amantadine and rimantadine — active against influenza A virus.
- Adapromine — acts on influenza A and B viruses.
- Deitiforin — has a combined effect on influenza A virus, parainfluenza 3 virus, and RSV.
- Tromantadine — used for herpes.
Remantadine works EARLY (early stage) and ONLY with A (influenza A). No M2 — no effect (influenza B).
Class and exam questions
Why is remantadine not prescribed for influenza B?
The influenza B virus genetically lacks the M2 protein that forms proton channels. Since the pharmacological target is physically absent, the drug is ineffective.
What is the pharmacokinetic advantage of remantadine over amantadine?
Remantadine has a longer half-life (24–36 hours) and undergoes intensive metabolism. It causes CNS side effects less frequently, although it also crosses the BBB.
Can enfuvirtide be used instead of remantadine for severe influenza?
No. Enfuvirtide is a fusion inhibitor specific exclusively to HIV. It has no effect on influenza viruses.
What else to study on this topic
- Neuraminidase inhibitors (oseltamivir, zanamivir) and the mechanism of disrupting viral release.
- The issue of resistance of modern influenza A virus strains to adamantane derivatives.
- Interferon inducers (kagocel) in the prevention and treatment of acute respiratory viral infections (ARVI).
- Broad-spectrum antiviral drugs (ribavirin): the mechanism of RNA and DNA synthesis inhibition, toxicity profile.
- Differential diagnosis of viral infections for evidence-based selection of targeted therapy.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Remantadine" and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.